Plus Therapeutics (NASDAQ:PSTV) Now Covered by Analysts at D. Boral Capital

D. Boral Capital started coverage on shares of Plus Therapeutics (NASDAQ:PSTV) in a report released on Monday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $9.00 price target on the stock.

Other research analysts also recently issued research reports about the stock. Ascendiant Capital Markets dropped their price objective on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research note on Monday, December 9th. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Plus Therapeutics in a research report on Tuesday, November 26th.

Plus Therapeutics Price Performance

NASDAQ PSTV opened at $0.59 on Monday. Plus Therapeutics has a 12 month low of $0.24 and a 12 month high of $2.67. The company has a 50-day moving average of $1.11 and a 200-day moving average of $1.25. The company has a market cap of $3.48 million, a P/E ratio of -0.23 and a beta of 0.73.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.